The authors have no financial disclosures for this article. All authors deny any financial or material support for their work. Likewise, all authors deny any financial interest in any company or entity concerned by this work.
Article first published online: 13 JAN 2011
Copyright © 2011 The American Laryngological, Rhinological, and Otological Society, Inc.
Volume 121, Issue 2, pages 335–338, February 2011
How to Cite
Desuter, G., Duprez, T., Huart, C., Gardiner, Q. and Verbruggen, G. (2011), The use of adalimumab for cricoarytenoid arthritis in ankylosing spondylitis—an effective therapy. The Laryngoscope, 121: 335–338. doi: 10.1002/lary.21343
The authors have no conflicts of interest to declare.
- Issue published online: 26 JAN 2011
- Article first published online: 13 JAN 2011
- Manuscript Accepted: 27 AUG 2010
- Manuscript Received: 24 AUG 2010
This report describes cartilaginous regeneration in a cricoarytenoid joint affected by spondyloarthropathy using tumor necrosis factor-alpha (TNF-α) blockade, monitored by magnetic resonance (MR) and computed tomography (CT) imaging. This case is interesting for several reasons. It is only the eighth case of destructive ankylosing spondylitis-related cricoarytenoid arthritis published in the English language literature. It describes, for the first time, full recovery of vocal cord mobility following TNF-α blockade. It is also the first case to be published with MR imaging demonstrating regeneration of the cricoarytenoid cartilage following treatment. This case represents a landmark in the treatment of patients presenting with destructive arthritis involving the cricoarytenoid joint.